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REPORTS 
Inhibition of Clonogenic Growth of Melanoma Cell's by Combination of 
Melanocyte Stimulating Hormone and Theophylline 
MICHAEL M. WICK, M .D ., PH.D. 
Division of Medical Oncology and Clinical Pharmacology, Sidney Farber Cancer Institute, and Department of Dermatology, 
Harvard Medical School 
The combination of MSH and theophylline is synergis-
tic in inhibiting the growth as well as stimulating the 
differentiation of pigmented melanoma cells. In order to 
determine if a permanent alteration in the proliferative 
potential of these cells was achieved, we examined the 
effect ofMSH and theophylline alone and in combination 
upon the plating efficiency and tumorigenicity of S-91 
Cloudman melanoma cells. Following treatment with the 
combination of MSH and theophylline, the cells became 
deeply pigmented and had their colony forming ability 
reduced to 28% of control. Neither MSH or theophylline 
alone, although effective in reducing the growth rate of 
the cells, caused a significant reduction in clonogenic 
growth. When cells were pretreated with MSH and theo-
phYlline alone or in combination and reinjected into 
mice, the combination of MSH and theophylline caused 
a significant reduction in percentage of animals devel-
oping tumor (reduced to 14% of control) . Cells treated 
with either MSH or theophylline alone were similar in 
their tumorigenic potential to control cells. These effects 
were selective since the nonmelanocytic control cells, 
mouse fibroblast L929 and Chinese hamster ovary when 
treated similarly did not exhibit any alteration in their 
clonogenic potential. The treatment of responsive cells 
with the combination of MSH and theophylline is capable 
of causing permanent decrease in the proliferative po-
tential of murine melanoma cells and may have rele-
vance to the treatment of this disease in man. 
Melanoma cells possess a unique biochemical apparatus for 
the oxidative conversion of tyrosine into the pigment melanin. 
This apparatus is under the control of cyclic AMP and there-
fore, agents that tend to raise the intracellular level of cyclic 
AMP such as dibutyrylcyclic AMP, papaverine, theophylline 
and MSH have shown to cause an increase in differentiation 
and pigmentation both in vivo and in vitro [1-5]. These agents 
tend to raise intracellular levels of cyclic AMP either directly 
by stimulating adenylate cyclase (MSH), or indirectly by in-
hibiting hydrolysis of cyclic AMP by cyclic nucleotide phospho-
diesterase (papaverine and theophylline). The effect of MSH, 
although modest, is restricted to the pigment cell and the 
combination of MSH and theophylline has been shown to be 
markedly synergistic in its effects upon both inhibition of cell 
growth as well as cell differentiation. Since the effect of MSH, 
although modest, is restricted to the pigment cell, the possibility 
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for the potential selective manipulation of this system by the 
combination of MSH and theophylline exists. 
The use of growth assays however does nut necessarily cor-
relate quantitatively with cell kill [6] since the effects upon 
growth rate might be reversible and indicate sublethal damage. 
MSH alone has been shown, in fact, to increase the plating 
efficiency of S-91B melanoma cells while inhibiting their growth 
[7]. 
In order to determine if the effects upon growth rate were 
reversible or whether a permanent alteration in the clonogenic 
potential of the cells was achieved, we examined the effect of 
MSH and theophylline both alone and in combination upon the 
clonogenic potential of S-91 Cloudman melanoma cells. The 
clonogenic potential of these cells was measured in vitro by a 
colony forming assay as well as by their ability to form tumors 
when reinjected into mice. 
MATERIALS AND METHODS 
Drugs 
Theophylline and L-dopa were from the Sigma Chemical Company 
(St. Louis, MO), a MSH was prepared synthetically and pUl'chased 
from Calbiochem Co. (LaJolla, CAl. Radioisotopes were from the New 
England Nuclear Co. (Boston, MA). All other chemicals were reagent 
grade and used without purification. 
Cell Lines 
The origin and maintenance of cell lines have been described in 
detail [7]. All cells were maintained as monolayers in McCoy's 5A 
medium supplemented with 15% fetal calf serum, 100 U / ml of strepto-
mycin and 100 J.Lg/rnl of penicillin. 
Experimental Cultures 
Exponentially growing cultures were harvested and plated in Linbro 
multiwell tissue culture trays. MSH (5 X 10- 2 roM) and/ or theophylline 
(1.0 mM) was added 24 hr after plating. Pharmacologic levels of MSH 
were used in excess of those required for maximal stimulation to allow 
for any nonhormonally mediated effects of MSH. For growth determi-
nations, triplicate cultures were harvested daily and cells counted in a 
Model Z Coulter counter. The technique for measuring L-dopa-["H] 
incorporation has been described [8]. 
Colony Forming Assays 
S-91 melanoma cells were treated for 5 days in the presence of MSH 
(5 x 10- 2 mM), theophylline (1.0 mM) or a combination of MSH and 
theophylline. Following treatment, cells were inocula ted into GO-mm 
Falcon Petri dishes containing previously equilibrated media. Cells 
\yere plated at a density sufficient to yield 200 colonies per plate. 
Following 10 days, the cells were stained with Giemsa and colonies 
containing at least 50 cells were counted. Control cells had a plating 
efficiency of 14%. Each value was determined in triplicate. 
Tumorigenicity Assay 
Following pretreatment as described above, 5 X 10" cells were inoc-
ulated subcutaneously to BDF, mice (Jackson Laboratory, Bar Harbor, 
ME). The tumors were harvested after 30 days. Animals that did not 
have tumor present at this time were observed for 60 additional days 
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before being listed as permanently without tumor. For these condit ions, 
10{ control cells will cpnsistenly yield tumors in greater than 90% of the 
animals injected. 
RESULTS 
Effects upon Cell Growth 
Figure 1 shows the effect of M8H, theophylline and the 
combination of M8H and theophylline upon the growth of 8-91 
B melanoma cells . MSH alone is relatively ineffective in in-
hibiting cell growth. The effect of theophylline alone is some-
what greater. The combination of M8H and theophylline is 
much more effective than either agent alone in inhibiting the 
growth of the murine melanoma cells. 
Table I summarizes the effects of M8H and theophylline 
upon the growth of melanoma and nonmelanocytic cells. As 
expected, MSH has no measurable effect upon CHO and L929 
cells. Interestingly, theophylline at 1.0 mM also has very little 
effect upon either CHO cells or mouse fibroblast line while the 
combination of M8H and theophylline shows no inhibitory 
effect. In contrast to these results, both theophylline and MSH 
caused an inhibition in melanoma cell growth as measured after 
72 hr of exposure; an effect significantly increased by combined 
treatment. Although theophylline is able to inhibit the growth 
of nonmelanocytic cells, the potentiation with MSH confIrmed 
that only those cells containing MSH receptors, i.e., melanoma 
cells exhibited syn ergy. 
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FIG 1. Effect of MSH (5 x 10- 2 mM) . (0 ), theophylline (1.0 mM) 
(0), combined treatment (.) and no treatment (e) upon the growth of 
S91 B melanoma cells respectively. Values represent the mean of 
triplicate determinations. 
TABLE 1. Comparison of growth inhibition by MSH and 
theophylline" for 891 melanoma, L929 fibroblast and CHO cells 
8-91 B 
CHO 
L929 
Cell 
line 
Theophylline 
(1 .0 nlM) 
46 ± 5 
15 ± 11 
15 ± 100 
MSH 
(5 x 10- 2 mM) 
34 ± 8 
o 
o 
MSH 
and 
theophylline 
86 ± 2 
o 
o 
" Values represent mean ± 8EM and are expressed as a percentage 
according to the ,formula : (# of contro l ceLls-#. of treated ce Lls)/# of 
control cells x 100, after 72 hr of exposure. Cells were at 1 x 10" /well 
were inoculated into multiwells and 24 hr later drugs were added and 
cells harvested after 72 hr of exposure. The population doubling times 
were S-91B (20 hr) CHO 13 hr L929 24 hr. The data represent the mean 
of 4 separate experiments. 
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FIG 2. L-Dopa-[:JH] incorporation by melanoma cells. The effect of 
MSH (5 x 10- 2 mM) (0 ), t heophylline (1.0 mM) (0), combined treat-
ment (.) and no treatment (e) upon incorporation of radioactively 
labeled L-dopa by S91 B melanoma cells. Control, and MSH treated 
cells show lit tle incorporation of radioactively labeled L-dopa. While 
treatment with theophylline and more importantly combined treatment 
resulted in marked increase in radioactively labeled levodopa incorpo-
ration. 
TABLE II. E ffect of M8H and theophylline pretreatment upon 
colony forming ability of 891 B melanoma cells 
Treatment 
Control 
M8H (5 x 10- 2 mM) 
Theophylline (1.0 mM) 
M8H and theophylline 
% of control 
(colonies)" 
100 (142 ± 12) 
94 (134 ± 10) 
132 (188 ± 4) 
28 (40 ± 24) 
" Values represent mean ± SEM for triplicate samples. Cells were 
treated for 5 days and repeated to yield approximately 200 colonies/60 
m Petri dish. Values represent the mean of 4 separate experiments. 
Differentiation 
A marked alteration in cellular morphology was observed 
with combined treatment. Cells were deeply pigmented with a 
large cytoplasm/nuclear ratio. The S-91 B line which normally 
did not manufacture detectable pigment could be induced to 
form extensive pigment under combined treatment. Treatment 
with MSH alone had li ttle effect upon pigment production 
while theophylline was more effective in inducing differentia-
tion. The incorporation of exogenous radiolabeled L-dopa is a 
property unique to melanoma cells and is a measure of their 
differentiated state. Figure 2 illustrates the incorporation of 
radiolabeled levodopa by melanoma cells treated with MSH, 
theophylline, or M8H and theophylline for 72 hr. The treat-
ment with MSH has little effect upon increasing the radioactive 
levodopa incorporation. Theophylline does result in significant 
increase in incorporation while the combination of MSH and 
theophylline results in a large increase in radioactive levodopa 
- incorporation paralleling the morphologic changes. 
Colony Formation 
Permanent changes in the proliferative potential of the cells 
are best measured by colony forming assays. We next examined 
the ability of 8-91 B cells treated for five days in the presence 
ofMSH and theophylline or their combination to form colonies. 
Table II summarizes a typical experiment. Plating efficiency of 
control cells was 14%. MSH and theophylline pretreatment did 
not significantly alter the colony forming ability of the cells. 
These results confIrm that effects upon growth inhibition do 
not necessarily correlate with permanent alteration in the pro-
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liferative potential of cells and that inhibit ion of growth can be 
reversible. However, the pretreatment with the combination of 
MSH and theophylline significantly reduce the colony forming 
a bility of the cells to 28% of control (P < 0.001). 
Tumorigenicity Assay 
The proliferative potential of cells can similarly be assayed 
b~ thei.r ability to form tumors when reinjected into compatible 
mice. The ability of pretreated cells to form tumors was mea-
sured. The S-91 B clone retains its abili ty to form tumors when 
injected into mice. As litt le as lOa cells will produce tumor in 
greater than 90% of t he animals. Table III summarizes the 
results of these experiments. Following pretreatment with 
MSH, theophylline or the combination, the cells were harvested 
and injected in to mice. Pretreatment with either MSH or 
theophylline alone had no significant effect upon the ability of 
the cells to form tumors, confIrming the results obtained in the 
colony forming assay. The combined treatment, however, 
greatly reduced the tumor forming ability of the cells with 
tumors rising in only 13% of the mice inoculated. Interestingly, 
pretreatment with MSH caused a reduction in mean tumor 
weight while theophylline had no significant effect upon the 
mean tumor weight. The results suggest that each bioassay 
method measures a somewhat different property of the mela-
noma cells. 
DISCUSSION 
Melanoma cells present a special opportunity to examine and 
utilize phenotypic expression for the manipulation of tumor 
growth. The high selectivity and moderate activity of MSH can 
be enhanced by combination with a general phosphodiesterase 
inhibitor such as theophylline. Selectivity is preserved and 
reflected by the complete absence of synergistic toxicity upon 
the nonmelanocytic control cells L-929 and CHO presumably 
because of the absence of MSH receptors in these cells. Impor-
tantly, in the case of melanoma celis, the marked synergistic 
TABLE III. Effect of M8H and theophylline upon tumorigenicity of 
8 ·91 melanoma cells 
Control 
MSH (5 x 10- 2 mM) 
Theophylline (1.0 mM) 
MSH and theophylline 
Control 
MSH (5 x 10- 2 mM) 
Theophylline (1.0 mM) 
MSH and theophylline 
Tumorsu 
Experiment #1 
12/ 15 
10/15 
10/ 15 
2/ 15 
Experiment #2 
14/15 
12/ 15 
12/ 15 
3/15 
Mean tumor weight (mg) 
270 ± 90 
130 ± 40 
330 ± 130 
20 ± 2 
300 ± 30 
190 ± 40 
310 ± 50 
25 ± 5 
a Represents number of mice developing tumors/number of mice 
inoculated. Tumor bearing mice were sacrificed at 30 days and remained 
under observation for 60 additional days. In each group 5 X 105 trypan 
blue excluding cells were inoculated. 
effect is also manifest in the irreversible decrease in the prolif-
erative potential of th ese cells as measured by colony .forming 
assays and tumorigenicity assays. Previous work by Kreider 
with B-16 melanoma suppor t the concept that cells stimulated 
by maturation agents can lose their ability to form tumors in 
vivo. 
The loss of proliferative potential is most likely related in 
part to the greatly elevated tyrosinase levels acting upon what 
is normally a nontoxic tyrosine concentration in the media. 
However, t heophylline, which is effective in increasing th e 
differentiated phenotypic expansion of these cells has little or 
no effect upon the proliferative potential. The combination of 
MSH and th eophylline may exert effects that are not obtainable 
with either agent alone and that simple elevation of the tyro-
sinase activity may not account entirely for the combined 
cytotoxicity. Theophylline has been shown to decrease both 
uridine and glucose transport across cell plasma membrane [9] 
as well as incorporate into DNA. 
The results presented h ere demonstrate that th e clonogenic 
potential of melanoma cells can be markedly reduced by th e 
combination of MSH and theophylline. Since these agents are 
essentially nontoxic and can be combined with conventional 
chemotherapeutic agents, an interesting alternate approach to 
the therapy of advanced disease is possible. Furthermore, since 
t~ese agents also caused a marked increase in pigment produc-
tIOn, the cells should be more sensitive to the antitumor activity 
of levodopa and dopamine analogs [10]. We are presently ana-
lyzing the clinical utility of t hese observations [11, 12]. 
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